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Abstract
One novel Kunitz BPTI-like peptide designated as BBPTI-1, with chymotrypsin 
inhibitory activity was identified from the venom of Burmese Daboia russelli siamensis. 
It was purified by three steps of chromatography including gel filtration, cation exchange 
and reversed phase. A partial N-terminal sequence of BBPTI-1, 
HDRPKFCYLPADPGECLAHMRSF was obtained by automated Edman degradation 
and a Ki value of 4.77 nM determined. Cloning of BBPTI-1 including the open reading 
frame and 3’ untranslated region was achieved from cDNA libraries derived from 
lyophilized venom using a 3’ RACE strategy. In addition a cDNA sequence, designated 
as BBPTI-5, was also obtained. Alignment of cDNA sequences showed that BBPTI-5
exhibited an identical sequence to BBPTI-1 cDNA except for an eight nucleotide 
deletion in the open reading frame. Gene variations that represented deletions in the 
BBPTI-5 cDNA resulted in a novel protease inhibitor analog. Amino acid sequence 
alignment revealed that deduced peptides derived from cloning of their respective 
precursor cDNAs from libraries showed high similarity and homology with other Kunitz 
BPTI proteinase inhibitors. BBPTI-1 and BBPTI-5 consist of 60 and 66 amino acid 
residues respectively, including 6 conserved cysteine residues.  As these peptides have 
been reported to have influence on the processes of coagulation, fibrinolysis and 
inflammation, their potential application in biomedical contexts warrants further 
investigation.
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1. Introduction
Protease inhibitors are part of the composition of Russell’s viper venom, in which 
they exhibit varying concentrations depending on their geographical distribution [21].
Trypsin and chymotrypsin inhibitors from snake venoms are members of the functionally 
diverse BPTI-like (bovine pancreatic trypsin inhibitor) superfamily. The snake venom 
Kunitz/BPTI inhibitors are basic polypeptides with approximately 60 amino acids in 
which there are six cysteine residues forming three conserved disulfide bridges. They 
exhibit diverse functions for inhibiting serine proteinase enzymes. This superfamily is 
classified into two families based on protein structure; small Kunitz-type inhibitors and 
BPTI-like toxins and soft tick anticoagulant proteins [5]. The Kunitz BPTI proteinase 
inhibitor family is divisible into subgroups according to source and bioactivity. Snake 
Kunitz/BPTI inhibitors have been divided into non-neurotoxic and neurotoxic groups 
according to their functions [2]. The non-neurotoxic snake Kunitz/BPTI inhibitors 
include trypsin and chymotrypsin inhibitors. Another group acting as K+ and Ca2+
channel blockers with little or no inhibitory activity is the neurotoxic snake Kunitz/BPTI. 
This group includes α-dentrotoxin, toxin K, toxin I, calcicludine, and the small subunit of 
β-bungarotoxin from various snake sources [11,14]. Moreover, a trypsin inhibitor 
occuring in a complex containing a phospholipase A2 (PLA2) and a protease has also 
been reported [22]. The characteristically folded domain like that of a BPTI-like peptides 
is also found in several proteins, for example a human Alzheimer amyloid precursor 
protein [17], type VI collagen alpha3(VI) [27,41], tissue factor pathway inhibitor [1] and 
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bikunin [38].
Although trypsin and chymotrypsin inhibitors are widely distributed in Russell’s 
viper venom, to date only some inhibitors have been cloned. Peptides belonging to the
Kunitz BPTI proteinase inhibitor family have very similar amino acid sequences, but 
display various functions. The present study describes the purification, properties, 
structure and cloning of chymotrypsin inhibitors from Burmese Daboia russelli 
siamensis venom. 
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2. Materials and methods
2.1 Materials
Burmese Daboia russelli siamensis venom was purchased from Xinyuan Jiayu 
management department for snake venoms (Guangzhou, China), an agency of Rainbow 
Snake Farm (Yingtan City, Jiangxi Province, China). A SuperdexTM Peptide 10/300 GL 
column was purchased from Pharmacia (Uppsala, Sweden). POROS 50HS gel was 
bought from Perkin Elmer (Wellesley, MA, USA). A Jupiter C18 column was purchased 
from Phenomenex Inc. (Torrance, CA, USA). Benzoyl-D, L-4-arginine-p-nitroanilide 
(BAPNA) was obtained from Shanghai ShuiYuan Biotechnology Co. Ltd. (Shanghai, 
China). N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide was bought from Sigma (Missouri, 
USA). Bovine trypsin and chymotrypsin were bought from Shanghai Sheng Gong 
Biological Engineering and Technology Service Co. Ltd. (Shanghai, China) and 
Amesco (Carson, CA, USA), respectively. A Micro BCATM Protein Assay Kit was 
obtained from Pierce Biotechnology Inc. (Rockford, Illinois, USA). A pGEM-T Easy 
vector and PCR Rapid Purification Kit were purchased from Promega (Madison, WI,
USA) while a DNA Sequencing Kit (BigDye Terminator v3.1) was obtained from 
Applied Biosystems (Foster City, California, USA). All reagents used were of analytical 
grade.
2.2. Isolation and Purification 
2.2.1. Pretreatment of crude venom by heating
One hundred milligrams of Burmese Daboia russelli siamensis venom were 
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dissolved in 1.0 ml of 0.4/99.6 (v/v) trifluoroacetic acid (TFA)/water. The venom 
solution was heated at 80 oC for 30 min in a water bath. The supernatant was prepared by 
centrifugation at 10,000 !  g for 10 min. The precipitate was washed twice using 0.4/99.6 
(v/v) TFA/water, then the supernatant was pooled and concentrated using a Christ Alpha 
rotating vacuum concentration centrifuge (Martin Christ, Osterode am Harz, German).
2.2.2. SuperdexTM Peptide 10/300 GL column chromatography
The concentrated supernatant was applied to a SuperdexTM Peptide 10/300 GL 
column (1.5! 30.0 cm) equilibrated with 0.02 M PBS buffer, pH 7.0, containing 0.25 M 
NaCl at a flow rate of 0.6 ml/min. The chromatography was conducted using a 
Beckman Gold HPLC system (Beckman Instruments, Brea, CA, USA) at room 
temperature, the eluate monitored at 214 nm using a Beckman 166 UV detector and 
fractions collected.2.2.3. POROS 50HS column chromatography
The fraction containing chymotrypsin inhibitor activity from gel filtration 
chromatography was collected and diluted four-fold (V/V) with 0.02 M phosphate buffer, 
pH 7.0. High performance liquid chromatography (HPLC) of the diluted fractions was
performed using a self-packed POROS 50HS column (0.6 ! 15.0 cm). The column was 
equilibrated with 0.02 M phosphate buffer, pH 7.0 at a flow rate of 1.0 ml/min. The 
absorbed components were eluted with a linear gradient of NaCl from 0 to 0.35 M in the 
equilibrium buffer for 140 min and 0.35 to 0.8 M NaCl for 100 min. The 
chromatography was conducted using a CCPD 8000 HPLC system from Tosoh Co. 
(Tokyo, Japan) at room temperature, the eluate was monitored at 214 nm with a 
Beckman 166 UV detector and fractions were collected.
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2.2.4. Purification of BBPTI-1 on reverse phase C-18 column
The fractions with inhibitory activity against chymotrypsin from the POROS 50HS 
column chromatography separation were loaded onto a Jupiter C-18 column (0.46 ! 15
cm) equilibrated with 0.05/99.95 (v/v) trifluoroacetic acid (TFA)/water at a flow rate of 
0.5 ml/min. The absorbed components were eluted with a linear gradient from
0.05/79.95/20 (v/v/v) TFA/water/80% acetonitrile to 0.05/65.45/34.5 (v/v/v) 
TFA/water/80% acetonitrile for 155 min. The chymotrypsin inhibitors were concentrated 
by using a ZFQ 85A rotating vacuum concentrator (Shanghai Medical Machine Ltd, 
China) and a Christ RVC rotating vacuum evaporator (Martin Christ, Osterode am Harz, 
Germany) for further characterization. POROS 50HS column chromatography was then 
performed as described above.
2.3. Characterization of BBPTI-1 
2.3.1. Mass spectrometry
MALDI-TOF MS of positive ions of trypsin inhibitors was carried out using a 
Voyager DE mass spectrometer (Voyager, Applied Biosystems, Warrington, UK) 
operated in linear mode. Alpha-cyano-4-hydroxycinnamic acid (Sigma, UK) (10 mg/ml) 
was prepared in a solution containing 0.1/49.9/50 TFA/water/acetonitrile. Calibration 
took place using a mixture of peptides of known mass (Laser Biolabs, Sophia-Antipolis, 
Cedex, France).
2.3.2. Determination of peptide concentration
A Micro BCATM Protein Assay Kit (Pierce, USA) was used for determination of 
peptide concentrations using BSA (supplied with the kit) as the standard according to the 
manufacturer’s protocol.
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2.3.3. Amino acid sequence from automated Edman degradation 
Sequence determination of purified peptide was performed by Edman degradation 
using a protein sequencer (Applied Biosystems Model 476A, Perkin Elmer, MA, USA). 
The primary structure was obtained by comparing the elution position of standard 
PTH-AAs. 
2.3.4. Determination of chymotrypsin inhibitory activity and chymotrypsin inhibition 
constants (Ki)
Chymotrypsin inhibitor activities were measured according to the Mikola and 
Mikkonen method [28] with modifications. Assays were performed by adding together 
30 ! l of 5.0 ! g/ml chymotrypsin solution (Amesco, USA), 10.0 ! l of sample solution, 
300.0 ! l of 0.2 M Tris-HCl buffer (pH 8.0) containing 0.02 M CaCl2 and 210.0 ! l of 
distilled water. After the mixture was preincubated at 37 oC for 20 min in a water bath, 
50 ! l of preheated substrate (1.5 mg/ml), N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide 
(Sigma, USA) were added to the assay solution and the mixture was further incubated at 
37 oC for 5 min. The enzymatic reaction was terminated by the addition of 60.0 ! l of 
30% acetic acid. Distilled water was used as the control. The mixture was centrifuged at 
10,000 !  g for 5 min, and its absorbance read at 405 nm.
For the determination of the chymotrypsin inhibitor Ki value, an appropriate amount 
of chymotrypsin was incubated with two concentrations of substrate. Briefly, the mixture 
contained 50 ! l of bovine chymotrypsin (5.0 ! g/ml), varying volumes of inhibitor also at 
a concentration of 5.0 ! g/ml, 300.0 ! l of 0.2 M Tris-HCl buffer (pH 8.0) containing 0.02 
M CaCl2 and an appropriate amount of distilled water to provide a total volume of 550.0 
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! l. After the mixture was incubated at 37 oC for 20 min in a water bath, 50.0 ! l of 
preheated substrate (1.2 mg/ml or 0.6 mg/ml) were added to the assay solution for a 
further incubation of 5 min. The enzymatic reaction was terminated by the addition of 
60.0 ! l of 30% acetic acid. References were obtained by adding acetic acid before the 
substrate was added to mixture. After the mixture was centrifuged at 10,000 !  g for 5 
min, its absorbance was read at 405 nm. A Dixon plot [10] of 1/v versus I inhibitor 
concentration at two substrate concentrations was performed to estimate the inhibition 
constant and to determine if any activity was competitive or non-competitive.  In such 
plots non-competitive activity is observed by lines converging on the x axis while for 
competitive activity lines converge above the x axis.
2.3.5. Detection of trypsin inhibition activity
Trypsin inhibitor activity was measured according to the Mikola and Mikkonen 
method [28] with modifications. Assays were performed by adding 50 ! l of trypsin
solution (5.0 ! g/ml), varying concentrations of inhibitor, 300.0 ! l of 0.2 M Tris-HCl 
buffer (pH 7.4) containing 0.02 M CaCl2, and distilled water to provide a final volume of 
550 ! l. After the mixture was preincubated at 37 oC for 20 min in a water bath, 50 ! l of 
preheated substrate (2.0 mM) (BAPNA) was added to the trypsin assay solution, and the 
mixture was further incubated at 37 oC for 5 min. The enzymatic reaction was terminated 
by the addition of 60.0 ! l of acetic acid. Distilled water was used as the control in place 
of protease inhibitor. After the mixture was centrifuged at 10,000 ! g for 5 min, its 
absorbance was read at 405 nm.
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2.4. Molecular cloning of cDNA encoding chymotrypsin inhibitors
2.4.1. Construction of cDNA libraries derived from lyophilized snake venom
An mRNA isolation kit (Dynal Biotec., ASA, Oslo, Norway) was used to isolate 
mRNA. Briefly, 50.0 mg of lyophilized Burmese Daboia russelli siamensis venom was 
dissolved in 1.0 ml of lysis/binding buffer. Magnetized oligo-dT beads were used to 
isolate mRNA with polyadenylate according to manufacturer’s protocol. The isolated 
mRNA was immediately used for a 3’-rapid amplification of cDNA ends (RACE) 
reaction to obtain the chymotrypsin inhibitor nucleic acid sequence based on a 
SMART-RACE kit (Clontech, Basingstoke, UK) method.
2.4.2. Cloning of protease inhibitors
A sense primer (P1) sequence (5’-ATGTCTTCTGGAGGTCTTCTTCTCC-3’) 
designed from the signal peptide was according to the B1 chain (BPTI peptide) cDNA of 
a PLA2 [37]. PCR product was obtained by utilizing a nested universal primer (NUP) (an 
antisense primer) from the kit and a sense primer, P1. PCR was performed on a thermal 
cycler (ThermoHybaid, Franklin, MA, USA) using the following cycle: initial denaturing 
at 94°C for 3 min, 40 cycles of PCR (94 oC for 30s, 57 oC for 30s, and 72 oC for 3 min). 
The last cycle was 72oC for 10 min. PCR product was analyzed by agarose gel 
electrophoresis. The 3-RACE reaction was purified by using the Wizard® SV Gel and 
PCR Clean-Up System (Promega, Madison, WI, USA). Purified PCR sample was 
transformed to pGEM-T Easy vector, and then cloned into JM 109 high efficiency 
competent cells (Promega, Madison, WI, USA) according to the protocol. Two primers 
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flanking the inserts in pGEM-T Easy vectors were used to amplify the inserted gene and 
for DNA sequencing. The inserted genes containing approximately 500 bps were 
selected for DNA sequencing by using a BigDye® Terminator v3.1 Cycle Sequencing 
Kit and an ABI 3100 automated DNA sequencer (Applied Biosystems, California, USA). 
2.5. Bioinformatics of nucleotide and amino acid sequences
The AlignX programme of the Vector NTI Bioinformatics suite (Informax) was 
used for alignment of nucleotide sequences cloned from Burmese Daboia russelli 
siamensis venom and its similar analogs, and for alignment of amino acid sequences 
deduced from cloned cDNAs. Regions of local similarity between sequences were 
determined by BLAST searching (http://www.ebi.ac.uk/Tools/sss/ncbiblast).
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3. Results
3.1. Purification of BBPTI-1
When Burmese Daboia russelli siamensis venom was dissolved in 0.4% TFA 
water and heated at 80oC in a water bath for 30 min, a significant amount of protein was 
precipitated and removed by centrifugation. Shown in Fig. 1a is the result of 
SuperdexTM Peptide 10/300 GL column chromatography of the pretreated sample. 
Several peaks are shown in the chromatogram, of which one marked with an arrowhead 
was found to display chymotrypsin inhibition activity. The active fractions were pooled, 
and diluted four-fold with 0.02 M phosphate buffer, pH 7.0, then applied to a cation 
exchange POROS 50HS column resulting in the chromatogram shown in Fig. 1b. Nine 
peaks were obtained in all, of which peak 5 showed chymotrypsin inhibition activity. 
The fractions corresponding to peak 5 were further purified on a C-18 column to purify 
the active peptide, BBPTI-1 (Fig. 1c). 
3.2 Properties of BBPTI-1
3.2.1. Mass spectrometry
Fig. 1d shows the MALDI-ToF mass spectrum of BBPTI-1, indicating that 
complete isolation of the chymotrypsin inhibitor peptide from crude venom had taken 
place. The mass spectral signal at 6872.81 m/z represents the singly charged state of the 
peptide ([M+H]+) while 3438.10 m/z represents the doubly charged state ([M+2H]2+).  
Deconvolution of these peaks provides masses for the peptide of 6874.20 Da as derived 
from the doubly charged signal and 6871.81Da from the singly charged state.  The 
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discrepancy in mass is most likely due to the MALDI-ToF instrument operating to 
approximately ± 0.1% accuracy and for this reason the mass of 6874.20 Da as derived 
from the doubly charged 3438.10 m/z signal is preferred as it is subject to a lower 
potential error.
3.2.2. Amino acid sequences of BBPTI-1
Using automated Edman degradation, the partial N-terminal amino acid sequence 
of BBPTI-1 was found to be HDRPKFCYLPADPGECLAHMRSF.
3.2.3. Determination of chymotrypsin inhibition constant
The Dixon plot in Fig 2 shows that BBPTI-1 has chymotrypsin inhibition activity 
with a Ki value of 4.77 nM. It was competitive in its activity with that of chymotrypsin 
as demonstrated in Fig. 2 by lines converging above the x axis (indicated by an 
arrowhead).
3.2.4. Trypsin inhibition activity
BBPTI-1 strongly inhibited chymotrypsin activity, but showed no detectable 
inhibitory activity against trypsin.
3.3. Molecular cloning of cDNA encoding BBPTI-1 and BBPTI-5
RT-PCR product with about 500 bps was obtained from the dry venom-derived 
libraries of Burmese Daboia russelli siamensis venom. Two cDNAs of BPTI peptides 
designated as BBPTI-1 and BBPTI-5, were consistently cloned from Burmese Daboia 
russelli siamensis venom by using one primer designed from the signal peptide, and 
another primer (NUP) from the kit for PCR analysis (Fig. 3A, Fig. 3B). The cDNA 
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sequences of BBPTI-1 and BBPTI-5 show an open-reading frame consisted of 84 and 90 
amino acid residues, respectively. Determination of the cDNA of purified BBPTI-1 was 
achieved by comparing the molecular mass and the N-terminal amino acid sequence of 
purified BBPTI-1 and the peptide sequence deduced from cDNA. In terms of molecular 
weight both are very similar.  Assuming that cysteines are oxidized, the deduced cDNA 
sequence has an average molecular weight of 6873.79Da while the molecular weight of 
the mature peptide as determined by MALDI-ToF mass spectrometry using the doubly 
charged signal (3438.10m/z) shown in Fig. 1d is 6874.20 Da. These two values are in 
very close agreement and demonstrate that oxidation of cysteines to form disulfide bonds 
has indeed taken place.  
3.4 Comparison of nucleotide and amino acid sequences and homology research 
Alignment of nucleotide sequences of BBPTI-1, BBPTI-5, CBPTI-3 from Chinese 
Daoboia russellii russellii venom and IBPTI-III from Indian Daoboia russellii russellii
venom (Fig. 4A) was performed by using the AlignX programme of the Vector NTI 
Bioinformatics suite (Life Technologies, UK). This revealed that these peptides have a 
high degree of similarity in nucleotide sequences in the translated signal peptide and 3’ 
untranslated regions. An obvious gene deletion compared to BBPTI-1 cDNA was found 
in the BBPTI-5 nucleotide sequence open-reading frame, which resulted in changing the 
site of the termination codon and producing BBPTI-5 with 66 amino acid residues. 
Alignment of BBPTI-1, BBPTI-5, CBPTI-3 and IBPTI-3 open-reading frame amino 
acid sequences (Fig. 4B) reveals they have a high degree of homology; in particular their 
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signal peptide sequences are identical. Fig. 4A shows that BBPTI-1 contains 60 amino 
acids with 6 cysteine residues, whose positions in the amino acid sequences are 
conserved in the four peptides investigated.
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4. Discussion
In snake venoms, there are many serine protease inhibitors belonging to the 
BPTI-like superfamily. To date a number of BPTI-like superfamily serine protease 
inhibitors from Viperidae and Elapidae venoms have been purified or characterized 
[3,4,12,13,15,16,18,19,25,26,29-31,32-34,35,36,39]. In this paper, one chymotrypsin 
inhibitor, BBPTI-1, was purified to homogeneity from the venom of Burmese Daboia 
russelli siamensis by gel filtration, cation exchange and reversed phase chromatography. 
The purified BBPTI-1 is basic and heat stable, which has been elucidated by the 
procedures of preparing venom samples and subsequent purification. The precursor 
cDNAs of BBPTI-1 and unknown BBPTI-5 have been cloned from libraries derived 
from Burmese Daboia russelli siamensis venom according to a method developed in our 
laboratory [6].
The venom of Burmese Daboia russelli simensis was heated at 80oC for 30 min, 
which resulted in the majority of protein being precipitated, so the purification 
procedures of BBPTI-1 became simpler. The molecular weight of BBPTI-1 is 6874 Da, 
(Fig. 1d) and is composed of 60 amino acid residues. BBPTI-1 showed competitive 
chymotrypsin inhibitory activity, but no detectable trypsin inhibitory activity. Generally, 
chymotrypsin inhibitors exhibit no inhibitory trypsin activity, as is the case with Oh11-1 
from Ophiophagus hannah venom [3], CBPTI-3 from Chinese Daboia russellii 
siamensis [13] and NA-CI from Naja atra venom [39], but Ritonja reported a 
chymotrypsin inhibitor that inhibited trypsin and human kallikrein weakly [31]. The 
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dissociation constant, Ki value of BBPTI-1 is similar to that reported for a chymotrypsin 
inhibitor from Vipera ammodytes venom of 4.3 nM [31], higher than CBPTI-3 from 
Chinese Daoia russullii siamensis venom, 2.55nM [13], but lower than the reported 
value for Oh11-1 from Ophiophagus hannah venom, 3.52 µM [3] and NA-CI from Naja 
atra venom, 25 nM [39].
The molecular weight of the mature BBPTI-1 peptide deduced from the cDNA 
sequence is 6873.79 Da (http://www.peptidesynthetics.co.uk/tools/) assuming that
cysteines are oxidized. This is in close agreement to the observed mass (6874.20Da) 
derived from MALDI-TOF mass spectrometry of the doubly charged signal (Fig. 1d). A 
comparison of cDNA of BBPTI-1, BBPTI-5, CBPTI-3 and IBPTI-III showed identical 
sequences in their signal peptide (Fig. 4B) and high similarity in the 3’-noncoding 
regions. A gene deletion compared to BBPTI-1 cDNA was found close to the 3’-terminal 
in BBPTI-5 cDNA, which resulted in a mature peptide with 66 amino acid residues. 
Following NCBI-BLAST (http://www.ebi.ac.uk/Tools/sss/ncbiblast/) mature peptide
homology searching, 6 amino acid differences were noted for BBPTI-1 compared to 
CBPTI-3 and 7 amino acid differences compared to IBPTI-3, especially for the P1
position; in BBPTI-1 this is Leu instead of Met in CBPTI-3 and IBPTI-3 (Fig. 4B). 
BBPTI-1 showed 90% similarity to CBPTI-3 (54/60) and 88% to IBPTI-3 (53/60). Naja 
naja atra chymotrypsin inhibitor (NACI) genes [8] and several B chain genes of 
β-bungarotoxins have been reported by Cheng et al. [7], and they share virtually an 
identical structural organization containing 3 exons and 2 introns, and a high degree of 
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sequence identity. This suggests that Kunitz/BPTI protease inhibitors and B chains may 
have originated from a common ancestor, as was also elucidated by comparing signal 
peptide amino acid sequences of snake Kunitz/BPTI proteins and obtain highly 
conserved sequences [40]. In this paper, highly conserved signal peptide sequences of 
Kunitz/BPTI proteins were also found (Fig. 4B). Moreover, by analyzing the protein 
sequences of the snake Kunitz/BPTI family, the progressive development of this family 
has been achieved by gene duplication followed by diversification [7,40].
With regard to the competitive inhibition activity study, the P1 residue in the center 
of the binding loop is particularly important and its variants have been shown to greatly 
alter the specificity and potential activity of these peptides [9,20]. The P1 amino acid in 
many inhibitor families shows a high degree of variability [24]. Cardle and Dufton [2]
analyzed the Kunitz BPTI proteinase inhibitor sequences for each subgroup containing 
different functions and revealed that amino acid side chains at interactive sites were 
conserved. A typical trypsin inhibitor has a positively charged Arg or Lys residue at P1, 
whereas a chymotrypsin inhibitor has a large hydophobic Phe, Leu, Met, Tyr, or Trp 
residue [23]. Two chymotrypsin inhibitors containing Asn at P1 were also found in 
Bungarus fasciatus venom [25] and Ophiophagus hannah venom [3]. In this study the P1
amino acid residue of BBPTI-1 and BBPTI-5 is leucine (Fig. 4B), providing further 
confirmation that these peptides are chymotrypsin inhibitors.
Snake venom Kunitz/BPTI inhibitors are considered to have influence on the 
processes of coagulation, fibrinolysis and inflammation [33] and protease inhibitors such 
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as the polypeptides aprotinin and ulinastatin, have been used in pharmacological contexts.
In this paper the properties, structure and cloning of chymotrypsin inhibitors from 
Burmese Daboia russelli siamensis venom have been described.
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(A)
M  S  S  G   G  L  L   L  L  L   G  L  L  T   L  W  A ·
1 ATGTCTTCTG GAGGTCTTCT TCTCCTGCTG GGACTCCTCA CCCTCTGGGC
· E  L  T   P  I  S  G  H  D  R   P  K  F   C  Y  L  P ·
51 AGAGCTGACC CCCATCTCCG GCCACGACCG TCCAAAGTTT TGTTATCTCC
·  A  D  P   G  E  C   L  A  H  M   R  S  F   Y  Y  D
101 CTGCTGATCC TGGAGAATGT TTGGCCCATA TGCGTAGTTT CTACTACGAC
 S  E  S  K   K  C  K   E  F  I   Y  G  G  C   H  G  N ·
151 TCGGAATCAA AGAAATGTAA AGAATTTATT TACGGTGGAT GCCATGGGAA
· A  N  K   F  P  S  R   D  K  C   R  Q  T   C  G  G  K ·
201 TGCCAACAAG TTTCCGAGCA GGGATAAATG TCGCCAGACC TGTGGTGGTA
·  *  
251 AGTAGCATCC GCAAAGGGGA GACCCACCTG AATTGGGTCT AATTCGCCAA
301 CTTCACTGAG AGGCGTTCCT TCTGTCCTGG ATTATTCTGG AGACCCTCCC
     351 CCCAAACCCG CCCTGGCTTC ATCCCTTCTG TTCTGCAATA AAGCTTTGTT
401 CTCGCTGCAA AAAAAAAAAA AAAAAAAAAA
(B)
M  S  S  G   G  L  L   L  L  L   G  L  L  T   L  W  A ·
1 ATGTCTTCTG GAGGTCTTCT TCTCCTGCTG GGACTCCTCA CCCTCTGGGC
· E  L  T   P  I  S  G   H  D  R   P  K  F   C  Y  L  P ·
51 AGAGCTGACC CCCATCTCCG GCCACGACCG TCCAAAGTTT TGTTATCTCC
·  A  D  P   G  E  C   L  A  H  M   R  S  F   Y  Y  D
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101 CTGCTGATCC TGGAGAATGT TTGGCCCATA TGCGTAGTTT CTACTACGAC
 S  E  S  K   K  C  K   E  F  I   Y  G  G  C   H  G  N ·
151 TCGGAATCAA AGAAATGTAA AGAATTTATT TACGGTGGAT GCCATGGGAA
· A  N  K   F  P  S  R   D  K  C   R  Q  T   C  G  A  S ·
201 TGCCAACAAG TTTCCGAGCA GGGATAAATG TCGCCAGACC TGTGGTGCAT
·  A  K  G   R  P  T   *  
     251 CCGCAAAGGG GAGACCCACC TGAATTGGGT CTAATTCGCC AACTTCACTG
     301 AGAGGCGTTC CTTCTGTCCT GGATTATTCT GGAGACCCTC CCCCCAAACC
     351 CGCCCTGGCT TCATCCCTTC TGTTCTGCAA TAAAGCTTTG TTCTCGCTGC
     401 AAAAAAAAAA AAAAAAAAAA AAAAAAA
Fig. 3
(A)
                 1                                               50
  BBPTI-1    (1) ATGTCTTCTGGAGGTCTTCTTCTCCTGCTGGGACTCCTCACCCTCTGGGC
  BBPTI-5    (1) ATGTCTTCTGGAGGTCTTCTTCTCCTGCTGGGACTCCTCACCCTCTGGGC
  CBPTI-3    (1) ATGTCTTCTGGAGGTCTTCTTCTCCTGCTGGGACTCCTCACCCTCTGGGC  
IBPTI-III    (1) ATGTCTTCTGGAGGTCTTCTTCTCCTGCTGGGACTCCTCACCCTCTGGGC
                 51                                             100
  BBPTI-1   (51) AGAGCTGACCCCCATCTCCGGCCACGACCGTCCAAAGTTTTGTTATCTCC
  BBPTI-5   (51) AGAGCTGACCCCCATCTCCGGCCACGACCGTCCAAAGTTTTGTTATCTCC
  CBPTI-3   (51) AGAGCTGACCCCCATCTCCGGCCACGACCGTCCAAAGTTTTGTTATCTCC
IBPTI-III   (51) AGAGCTGACCCCCATCTCCGGCCACGACCGTCCAAAGTTTTGTTATCTCC
                 101                                            150
  BBPTI-1  (101) CTGCTGATCCTGGAGAATGTTTGGCCCATATGCGTAGTTTCTACTACGAC
  BBPTI-5  (101) CTGCTGATCCTGGAGAATGTTTGGCCCATATGCGTAGTTTCTACTACGAC
  CBPTI-3  (101) CTGCTGATCCTGGAGAATGTATGGCCTATATCCGTAGTTTCTACTACGAC
IBPTI-III  (101) CTGCTGATCCTGGAGAATGTATGGCCTATATCCGTAGTTTCCACTACGAC
                 151                                            200
  BBPTI-1  (151) TCGGAATCAAAGAAATGTAAAGAATTTATTTACGGTGGATGCCATGGGAA
  BBPTI-5  (151) TCGGAATCAAAGAAATGTAAAGAATTTATTTACGGTGGATGCCATGGGAA
  CBPTI-3  (151) TCGGAATCAAAGAAATGTAAAGAATTTATTTACGGTGGATGCCATGGGAA
IBPTI-III  (151) TCGGAATCAAAGAAATGTAAAGAATTTATTTACGGTGGATGCCATGGGAA
                 201                                            250
  BBPTI-1  (201) TGCCAACAAGTTTCCGAGCAGGGATAAATGTCGCCAGACCTGTGGTGGTA
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  BBPTI-5  (201) TGCCAACAAGTTTCCGAGCAGGGATAAATGTCGCCAGACCTGTGGT----
  CBPTI-3  (201) TGCCAACAATTTTCCGACCAGGGATAAATGTCGCCAGACCTGTCGTGGTA
IBPTI-III  (201) TGCCAACAATTTTCCGACCAGGGATAAATGTCGCCAGACCTGTCGTGGTA
                 251                                            300
  BBPTI-1  (251) AGTAGCATCCGCAAAGGGGAGACCCACCTGAATTGGGTCTAATTCGCCAA
  BBPTI-5  (247) ----GCATCCGCAAAGGGGAGACCCACCTGAATTGGGTCTAATTCGCCAA
  CBPTI-3  (251) AGTAGCACCCAGAAAGGGGAGACACACCTGAATTGGGTCTAATTCGCCAA
IBPTI-III  (251) AGTAGCACCCAGAAAGGGGAGACACACCTGAATTGCATCTAATTCGCCAA
                 301                                            350
  BBPTI-1  (301) CTTCACTGAGAGGCGTTCCTTCTGTCCTGGATTATTCTGGAGACCCTCCC
  BBPTI-5  (293) CTTCACTGAGAGGCGTTCCTTCTGTCCTGGATTATTCTGGAGACCCTCCC
  CBPTI-3  (301) CTTCACTGAGAGGCGTTCCTTCTGTCCTGGATTATTCTGGAGACCCTCCC
IBPTI-III  (301) CTTCACTGAGAGGCGTTCCTTCTGTCCTGGATTATTCTGGAGTCCCTCCC
                 351                                            400
  BBPTI-1  (351) CCCAAACCCGCCCTGGCTTCATCCCTTCTGTTCTGCAATAAAGCTTTGTT
  BBPTI-5  (343) CCCAAACCCGCCCTGGCTTCATCCCTTCTGTTCTGCAATAAAGCTTTGTT
  CBPTI-3  (351) CCCAAACCCGCCCTGGCTTCATCCCTTCTGTTCTGCAATAAAGCTTTGTT
IBPTI-III  (351) CGCAAACCCGCCCTGGCTTCATCCCTTCTGTTCTGCAATAAAGCTTTGTT
                 401                             435
  BBPTI-1  (401) CTCGCTGCAAAAAAAAAAAAAAAAAAAAAA-----
  BBPTI-5  (393) CTCGCTGCAAAAAAAAAAAAAAAAAAAAAAAAAAA
  CBPTI-3  (401) CTCGCTGCAAAAAAAAAAAAAAAAAAAAAA-----
IBPTI-III  (401) CTCGCTCCAAAAAAAAAAAAAAAAAAA--------
(B)
                1                                               50
  BBPTI-1   (1) MSSGGLLLLLGLLTLWAELTPISGHDRPKFCYLPADPGECLAHMRSFYYD
  BBPTI-5   (1) MSSGGLLLLLGLLTLWAELTPISGHDRPKFCYLPADPGECLAHMRSFYYD
  CBPTI-3   (1) MSSGGLLLLLGLLTLWAELTPISGHDRPKFCYLPADPGECMAYIRSFYYD
IBPTI-III   (1) MSSGGLLLLLGLLTLWAELTPISGHDRPKFCYLPADPGECMAYIRSFHYD
                51                                    90
  BBPTI-1  (51) SESKKCKEFIYGGCHGNANKFPSRDKCRQTCGGK------
  BBPTI-5  (51) SESKKCKEFIYGGCHGNANKFPSRDKCRQTCGASAKGRPT
CBPTI-3    (51) SESKKCKEFIYGGCHGNANNFPTRDKCRQTCRGK------
IBPTI-III  (51) SESKKCKEFIYGGCHGNANNFPTRDKCRQTCRGK------
Fig. 4
Page 31 of 32
Ac
ce
pte
d M
an
us
cri
pt
32
Fig. 1. Chromatographic and mass spectrometric profiles of BBPTI-1 purified from the venom of 
Burmese Daboia russellii siamensis. (a) Size exclusion HPLC profile of prepared Burmese Daboia 
Russelii siamensis venom. (b) Poros 50 HS cation exchange column purification of protease inhibitor 
fraction from size exclusion chromatography. (c) HPLC profile of components displaying 
chymotrypsin inhibition on a reversed phase C-18 column. (d) MALDI-TOF mass spectrum of 
purified BBPTI-1.
Fig. 2 Dixon plot showing inhibitory effects of BBPTI-1 on chymotrypsin activity on 
N-succinyl-Ala-Ala-Pro-Phe-ρ-nitroanilide in the presence of substrate at concentrations of 0.08 mM 
and 0.16 mM, respectively. Convergence of the lines above the x axis shows competitive activity
(indicated by an arrowhead).
Fig. 3. cDNAs and deduced amino acid sequences of BBPTI-1 (A) and BBPTI-5 (B)
precursors. Mature peptide sequence are denoted in bold. The sequence underlined 
was confirmed by automated Edman degradation. A stop code is indicated by an 
asterisk.
Fig. 4. Alignment of nucleotide sequences (A) and amino acid sequences (B) of BBPTI-1 (GenBank 
accession no. GenBank: AM411368), BBPTI-5 (GenBank accession no. GenBank: AM411372), 
CBPTI-3 (GenBank accession no. GenBank: AM411363) and IBPTI-III (GenBank accession no. 
GenBank: DQ365980). Identical bases and amino acids in all sequences are shaded in black while 
similar base and amino acid sequences are shaded in grey or in white. The arrow indicates the critical 
residue (site P1) of the antiprotease loop. Gaps are inserted for optimal alignment. 
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Highlights
► A novel chymotrypsin inhibitor, BBPTI-1, was found in Burmese Daboia russellii siamensis
venom
► BBPTI-1 showed strong chymotrypsin inhibition activity, but no trypsin inhibition activity
►BBPTI-1 was cloned along with another cDNA with an 8 nucleotide deletion
